Severe and fatal adverse events of immune checkpoint inhibitor combination therapy in patients with metastatic renal cell carcinoma: a systematic review and meta-analysis

IntroductionImmune checkpoint inhibitor (ICI) combination therapy has changed the treatment landscape for metastatic renal cell carcinoma (mRCC). However, little evidence exists on the treatment-related severe adverse events (SAEs) and fatal adverse events (FAEs) of ICI combination therapy in mRCC.M...

Mô tả đầy đủ

Chi tiết về thư mục
Những tác giả chính: Yao-Ning Feng, Guang-Yu Xie, Li Xiao, Dun-Chang Mo, Jian-Feng Huang, Peng-Hui Luo, Xiu-Juan Liang
Định dạng: Bài viết
Ngôn ngữ:English
Được phát hành: Frontiers Media S.A. 2023-06-01
Loạt:Frontiers in Immunology
Những chủ đề:
Truy cập trực tuyến:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1196793/full